Sign inCreate account

Report workspace tools

NCT00598663COMPLETEDanonymous

Randomized, Cross Over, Controlled, Multi-centric Study to Assess Whether Type 1 Diabetic Patients in Sub-optimal Glycemic Control Can Improve Using the Continuous Glucose Values of the MiniMed Paradigm REAL-Time Insulin Pump System Versus the MiniMed Paradigm Insulin Pump

Sponsor

Source record

Medtronic MiniMed, Inc.

Phase

Source record

Completed

Modality

AI-normalized

medical device

Target

AI-normalized

Continuous glucose monitoring in Type 1 diabetes management

Indication / condition

AI-normalized

Diabetes Mellitus, Type 1

Intervention

Source record

insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System), insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)

Source & freshness

Source record

NCT ID

NCT00598663

Original source

ClinicalTrials.gov

Source last updated

Sep 16, 2019

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00598663

Title

Randomized, Cross Over, Controlled, Multi-centric Study to Assess Whether Type 1 Diabetic Patients in Sub-optimal Glycemic Control Can Improve Using the Continuous Glucose Values of the MiniMed Paradigm REAL-Time Insulin Pump System Versus the MiniMed Paradigm Insulin Pump

Sponsor

Medtronic MiniMed, Inc.

Status

COMPLETED

Phase

Completed

Condition raw

Diabetes Mellitus, Type 1

Condition normalized

Diabetes Mellitus, Type 1

Modality raw

medical device

Modality normalized

medical device

Target raw

Continuous glucose monitoring in Type 1 diabetes management

Target normalized

Continuous glucose monitoring in Type 1 diabetes management

Interventions

insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System), insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)

Public preview

Source record

The SWITCH study, sponsored by Medtronic MiniMed, Inc., evaluates the efficacy of the MiniMed Paradigm REAL-Time Insulin Pump System with continuous glucose monitoring (CGM) versus the standard insulin pump with self-monitoring blood glucose (SMBG) in patients with Type 1 diabetes exhibiting sub-optimal glycemic control. Given the increasing prevalence of diabetes and the growing demand for advanced diabetes management technologies, this study positions Medtronic favorably within the competitive landscape of diabetes care devices. The results may enhance Medtronic's market share and reinforce its product offerings in the CGM space, particularly as healthcare providers and patients seek improved glycemic control solutions. Diligence should focus on the regulatory landscape and potential reimbursement pathways for CGM technologies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Randomized, Cross Over, Controlled, Multi-centric Study to Assess Whether Type 1 Diabetic Patients in Sub-optimal Glycemic Control Can Improve Using the Continuous Glucose Values of the MiniMed Paradigm REAL-Time Insulin Pump System Versus the MiniMed Paradigm Insulin Pump

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00598663

Status

COMPLETED

Phase

Completed

Sponsor

Medtronic MiniMed, Inc.

Executive brief

Investment-Ready Snapshot

The SWITCH study, sponsored by Medtronic MiniMed, Inc., evaluates the efficacy of the MiniMed Paradigm REAL-Time Insulin Pump System with continuous glucose monitoring (CGM) versus the standard insulin pump with self-monitoring blood glucose (SMBG) in patients with Type 1 diabetes exhibiting sub-optimal glycemic control. Given the increasing prevalence of diabetes and the growing demand for advanced diabetes management technologies, this study positions Medtronic favorably within the competitive landscape of diabetes care devices. The results may enhance Medtronic's market share and reinforce its product offerings in the CGM space, particularly as healthcare providers and patients seek improved glycemic control solutions. Diligence should focus on the regulatory landscape and potential reimbursement pathways for CGM technologies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 16, 2019
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00598663

Indication

Diabetes Mellitus, Type 1

Modality

medical device

Target

Continuous glucose monitoring in Type 1 diabetes management

Intervention

insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System), insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.